Detalles de la búsqueda
1.
Identification of the atypically modified autoantigen Ars2 as the target of B-cell receptors from activated B-cell-type diffuse large B-cell lymphoma.
Haematologica
; 106(8): 2224-2232, 2021 08 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32675228
2.
Age-dependent increase of treatment-related mortality in older patients with aggressive B cell lymphoma: analysis of outcome, treatment feasibility, and toxicity in 1171 elderly patients with aggressive B cell lymphoma-data from phase II and III trials of the DSHNHL (German High-Grade Non-Hodgkin's Lymphoma Study Group).
Ann Hematol
; 100(4): 1031-1038, 2021 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-33242101
3.
Optimization of rituximab for the treatment of DLBCL: increasing the dose for elderly male patients.
Br J Haematol
; 179(3): 410-420, 2017 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-28990173
4.
A 70% cut-off for MYC protein expression in diffuse large B cell lymphoma identifies a high-risk group of patients.
Haematologica
; 105(11): 2667-2670, 2020 11 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33131258
5.
Role of radiotherapy to bulky disease in elderly patients with aggressive B-cell lymphoma.
J Clin Oncol
; 32(11): 1112-8, 2014 Apr 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-24493716
6.
Rituximab for the treatment of diffuse large B-cell lymphomas.
Expert Rev Anticancer Ther
; 6(8): 1175-86, 2006 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-16925484
Resultados
1 -
6
de 6
1
Próxima >
>>